Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 10/20 | 0.57 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.54 |
| ▸ | RPA1 | P27694 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | BCL2 | P10415 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22892018 | 0.88 | CA9 (0.58) | KDM1ACA9CHRNA7RPA1FAAH | |
| SCHEMBL9206997 | 0.88 | CHRNA7 (0.70) | KDM1ACA9CHRNA7RPA1FAAH | |
| SCHEMBL5148820 | 0.87 | CA9 (0.57) | KDM1ACA9CHRNA7RPA1FAAH | |
| SCHEMBL8922991 | 0.86 | CA9 (0.56) | KDM1ACA9CHRNA7RPA1FAAH | |
| SCHEMBL20820086 | 0.84 | KDM1A (0.60) | KDM1ACA9CHRNA7FAAH | |
| SCHEMBL5524647 | 0.81 | KMT2A (0.52) | KDM1ACA9CHRNA7RPA1FAAH | |
| SCHEMBL16876862 | 0.81 | CA9 (0.55) | KDM1ACA9CHRNA7RPA1FAAH | |
| SCHEMBL18865603 | 0.80 | GAA (0.49) | CA9CHRNA7 | |
| SCHEMBL16797270 | 0.80 | KMT2A (0.52) | CA9 | |
| SCHEMBL5528274 | 0.80 | CA9 (0.52) | CA9CHRNA7RPA1FAAHBCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681877-B1 | PYRAZOLE DERIVATIVE COMPOUND AND USE THEREOF | HANMI PHARMACEUTICAL CO LTD (KR) | 2024-10-16 | — | — | EP | disclosed |
| CN-111094265-B | Pyrazole derivative compound and use thereof | 韩美药品株式会社 | 2023-07-25 | — | — | CN | disclosed |
| US-11254676-B2 | Pyrazole derivative compound and use thereof | HANMI PHARM. CO., LTD. (KR) | 2022-02-22 | — | — | US | disclosed |
| US-11254676-B2 | Pyrazole derivative compound and use thereof | HANMI PHARM. CO., LTD. (KR) | 2022-02-22 | — | — | US | disclosed |
| US-20210009591-A1 | PYRAZOLE DERIVATIVE COMPOUND AND USE THEREOF | HANMI PHARM. CO., LTD. (KR) | 2021-01-14 | — | — | US | disclosed |
| US-20210009591-A1 | PYRAZOLE DERIVATIVE COMPOUND AND USE THEREOF | HANMI PHARM. CO., LTD. (KR) | 2021-01-14 | — | — | US | disclosed |
| EP-3681877-A1 | PYRAZOLE DERIVATIVE COMPOUND AND USE THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2020-07-22 | — | — | EP | disclosed |
| CN-111094265-A | Pyrazole derivative compound and use thereof | 韩美药品株式会社 | 2020-05-01 | — | — | CN | disclosed |
| WO-2019054766-A1 | PYRAZOLE DERIVATIVE COMPOUND AND USE THEREOF | HANMI PHARM. CO., LTD. (KR) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009591-A1 | PYRAZOLE DERIVATIVE COMPOUND AND USE THEREOF | KDM1A, KDM3A, KDM1B | KDM1A 1/4885CA9 3556/4885CHRNA7 2344/4885 |
| US-11254676-B2 | Pyrazole derivative compound and use thereof | KDM1A, KDM3A, KDM1B | KDM1A 1/4885CA9 3556/4885CHRNA7 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.